Speciality Medicines Reports H1 FY27 Results with Revenue Growth and Zero Tax Provision
Speciality Medicines Ltd · Outcome · 12 Nov 2026, 9:56 pm
Speciality Medicines Reports H1 FY27 Results with Revenue Growth and Zero Tax Provision Speciality Medicines Limited reported standalone net revenue from operations of ₹8,695.10 lakh for the half-year ended 30th Sep'26, up 185.07% YoY compared to ₹3,050.17 lakh in H1 FY26 and 94.16% QoQ versus ₹4,478.34 lakh in H2 FY26. Net profit rose to ₹888.49 lakh from ₹485.02 lakh in H1 FY26, with basic and diluted EPS at ₹10.11. The company claimed 100% tax deductions under Section 80-IAC as a DPIIT-recognized startup, resulting in zero corporate tax provision. Additionally, ₹1,795.09 lakh of the ₹2,914.00 lakh IPO proceeds were utilized without deviations.
Original exchange filing (PDF)
More announcements from Speciality Medicines Ltd
- We hereby submit the Standalone Unaudited Financial Result for the half year ended on September 30, 2026 · 12 Nov 2026
- Speciality Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/11/2026 ,inter alia, to consider and approve 1. Unaudited Standalone .... · 12 Nov 2026
- We hereby submit Voting Results and Consolidated Scrutinizer report of the 5th AGM of the Company. · 28 Sept 2026
- We hereby submit Proceedings of 5th AGM of the Company. · 28 Sept 2026
- We hereby Submit Annual Report of FY 2025-26. · 04 Sept 2026
- We hereby submit Notice of 5th AGM to be held on September 28, 2026. · 04 Sept 2026
- We hereby submit Outcome of the board meeting held on September 03, 2026 · 03 Sept 2026
- We hereby submit intimation regarding approval for Two new products in Ethiopia. · 12 Aug 2026
